Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 4

Arterial Stiffness and Pharmacological Interventions – The TRanscend Arterial stiffNess Substudy (TRANS study)

Authors Jirar Topouchian, Ramzi El Feghali, Bruno Pannier, Shuyu Wang, Feng Zhao, Karel Smetana, Koon Teo, Roland Asmar

Published Date October 2007 Volume 2007:3(4) Pages 381—388

DOI http://dx.doi.org/

Published 4 October 2007

Jirar Topouchian1, Ramzi El Feghali1, Bruno Pannier1, Shuyu Wang2, Feng Zhao3, Karel Smetana4, Koon Teo3, Roland Asmar1

1The CardioVascular Institute, Paris, France; 2Beijing Clinical Trial and Research Center, Beijing, China; 3Population Health Research Institute, Hamilton, Canada; 4Vojenska nemocnice Plzen, Pizen, Czech Republic

Abstract: The degree of arterial stiffness is correlated with the risk of cardiovascular diseases and it is a powerful predictor for morbidity and mortality. Studies have shown that arterial stiffness reduction is associated with an improvement in survival. Reduction of arterial stiffness by pharmacological drugs varies according to the drugs and doses used and duration of treatment. This effect on the arteries differs among the various classes of drugs and among individual drugs in the same class. Quantification of the stiffness and other properties of the arterial wall can be used to monitor the responses to therapy in individuals with hypertension and other cardiovascular diseases. These measures can then be used as surrogate markers for the risk of clinical events. Inhibition of the renin-angiotensin system (RAS) is associated with an important decrease in cardiovascular risk. Findings from clinical trials support the hypothesis that the protective effects of RAS inhibition are partly independent from blood pressure reduction and related to several mechanisms including vascular protective effects. The aim of the TRanscend Arterial stiffNess Substudy (TRANS) is to assess the effect of an angiotensin II receptor blocker (ARB), telmisartan, on the arterial stiffness in a subgroup of patients from the Telmisartan Randomized Assessment Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) trial. The TRANSCEND trial is an international, multicenter, randomized double blind placebo controlled trial of telmisartan that enrolled patients at high risk for cardiovascular events. Some clinical baseline data of the TRANS substudy are reported. When completed, the results of the TRANS substudy will show whether the beneficial effects of treatment with telmisartan on cardiovascular outcome may be related to an improvement in arterial stiffness.

Keywords: arterial stiffness, cardiovascular prevention, ARBs, telmisartan, pulse wave velocity, antihypertensive

Download Article [PDF] 

Readers of this article also read:

Corrigendum

Sailasuta N, Harris K, Tran T, Ross B

Neuropsychiatric Disease and Treatment 2011, 7:707-708

Published Date: 25 November 2011

Transradial approach to lower extremity interventions

Ravikiran Korabathina, Sidharth S Yadav, John T Coppola, et al

Vascular Health and Risk Management 2010, 6:503-509

Published Date: 1 July 2010

Update on stents: Recent studies on the TAXUS® stent system in small vessels

Shuzou Tanimoto, Joost Daemen, Patrick W Serruys

Vascular Health and Risk Management 2007, 3:481-490

Published Date: 4 October 2007

Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients

Ana T Rocha, Edison F Paiva, Arnaldo Lichtenstein, Rodolfo Milani Jr, Cyrillo Cavalheiro-Filho,
Francisco H Maffei

Vascular Health and Risk Management 2007, 3:533-553

Published Date: 4 October 2007

Sirolimus-eluting coronary stents: a review

Alexandre Abizaid

Vascular Health and Risk Management 2007, 3:191-201

Published Date: 23 May 2007

Hypothyroidism in coronary heart disease and its relation to selected risk factors

Otto Mayer Jr, Jaroslav Šimon, Jan Filipovský, Markéta Plášková, Richard Pikner

Vascular Health and Risk Management 2006, 2:499-506

Published Date: 2 March 2006

Management of cancer-associated venous thrombosis

Ozlem Er, Leo Zacharski

Vascular Health and Risk Management 2006, 2:351-356

Published Date: 1 March 2006